SCHEDULE: Mizuho Financial Group Files Schedule 13G

Mizuho Financial Group, Inc. has filed a Schedule 13G, reporting beneficial ownership of 6.0% of Drugs Made In America Acquisition Corp. common shares.

Summary

• Mizuho Financial Group, Inc. has filed a Schedule 13G, indicating it is a parent holding company.
• The filing reports beneficial ownership of 2,000,000 shares of common stock in Drugs Made In America Acquisition Corp.
• This ownership represents 6.0% of the class of securities.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
• Takahiro Katsura, Managing Director at Mizuho Financial Group, Inc., has been granted power of attorney to execute and file necessary forms, including Form 13G, with the SEC on behalf of Mizuho Financial Group, Inc., Mizuho Bank, Ltd., Mizuho Americas LLC, and Mizuho Securities USA LLC.
• Mizuho Financial Group, Inc., Mizuho Bank, Ltd., and Mizuho Americas LLC may be deemed indirect beneficial owners of securities held by Mizuho Securities USA LLC, their wholly-owned subsidiary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine regulatory disclosure of ownership and does not contain operational or financial performance information.

Positives

• Mizuho Financial Group, Inc. is acting in compliance with SEC regulations by filing the Schedule 13G.
• The filing clarifies Mizuho's ownership stake and confirms it is not for the purpose of influencing control.

Risks

• The filing does not detail specific risks associated with the investment in Drugs Made In America Acquisition Corp.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance.

Management Comments

• Mizuho Financial Group, Inc., Mizuho Bank, Ltd. and Mizuho Americas LLC may be deemed to be indirect beneficial owners of said equity securities directly held by Mizuho Securities USA LLC which is their wholly-owned subsidiary.
• Takahiro Katsura, Managing Director, Global Corporate Function Coordination Department, certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that this filing is a standard disclosure for institutional investors exceeding certain ownership thresholds, indicating Mizuho Financial Group's compliance with regulatory requirements for reporting significant holdings.

Stakeholder Impact

• Shareholders of Drugs Made In America Acquisition Corp. are informed of Mizuho Financial Group's significant ownership stake.
• Regulators are assured of Mizuho Financial Group's compliance with reporting requirements.

Next Steps

• Mizuho Financial Group, Inc. will continue to file necessary amendments to Form 13G as required by the Exchange Act.
• The power of attorney granted to Takahiro Katsura remains in effect until Mizuho is no longer required to file Forms 13G for the company's securities.

Key Dates

Keywords

Schedule 13G, Mizuho Financial Group, Mizuho Bank, Mizuho Americas, Mizuho Securities USA, Drugs Made In America Acquisition Corp., Beneficial Ownership, SEC Filing, Parent Holding Company, Form 13G